CTS Corporation (CTS) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary indicates strong financial performance with increased sales in key markets like Medical and Industrial. Despite a decline in Transportation, new business awards and operational efficiencies improved EBITDA margins. The Q&A session highlighted strong demand and product development, though some management responses lacked clarity. Overall, the positive sales growth, improved margins, and strategic advancements in diversified markets suggest a positive stock price movement in the short term.
Key Financial Performance
Revenue (Q4 2025) $137 million, up 9% year-over-year. Growth driven by diversified end markets, which grew 16%.
Revenue (Full Year 2025) $541 million, up 5% from $515 million in 2024. Growth attributed to diversified end markets and operational improvements.
Book-to-Bill Ratio (Q4 2025) 1, up 3% year-over-year. Indicates sustained customer demand across diversified portfolio.
Book-to-Bill Ratio (Full Year 2025) 1.04, up from 1.01 in 2024. Reflects sustained demand across diversified markets.
Gross Margin (Q4 2025) 39.1%, up 150 basis points year-over-year. Improvement driven by operational efficiencies and favorable end market mix.
Gross Margin (Full Year 2025) 38.5%, up 150 basis points year-over-year. Driven by operational improvements and favorable end market mix.
Adjusted Diluted Earnings (Q4 2025) $0.62 per share, up from $0.50 in Q4 2024. Reflects focus on profitable growth.
Adjusted Diluted Earnings (Full Year 2025) $2.23 per share, up from $2.12 in 2024. Growth driven by operational improvements and diversified market performance.
Medical Market Sales (Q4 2025) Increased 41% year-over-year. Growth driven by strong demand in therapeutic applications.
Medical Market Sales (Full Year 2025) $85 million, up 21% from $70 million in 2024. Growth attributed to therapeutic applications and minimally invasive technologies.
Aerospace and Defense Sales (Full Year 2025) $83 million, up 20% from $69 million in 2024. Growth driven by backlog and new orders for naval sonar and RF filters.
Aerospace and Defense Sales (Q4 2025) Down 4% year-over-year. Decline due to timing of certain programs.
Industrial Market Sales (Q4 2025) Up 16% year-over-year. Growth driven by recovery in industrial activity and OEM demand.
Industrial Market Sales (Full Year 2025) $140 million, up 12% from $125 million in 2024. Growth driven by stabilization in industrial activity and distribution.
Transportation Sales (Full Year 2025) $234 million, down 7% from $250 million in 2024. Decline due to market dynamics in China and commercial vehicle market.
Transportation Sales (Q4 2025) $56 million, flat year-over-year. Despite sluggish market conditions, new business awards were secured.
Adjusted EBITDA Margin (Full Year 2025) 22.8%, up 40 basis points year-over-year. Improvement driven by operational efficiencies and diversified market growth.
Operating Cash Flow (Q4 2025) $29 million. Reflects strong cash generation.
Operating Cash Flow (Full Year 2025) $102 million. Reflects strong cash generation and operational performance.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Medical ultrasound and therapeutic products: Multiple wins across all regions for medical ultrasound and a large win for therapeutic products. Demand remains strong for therapeutic products, with increased volumes expected in 2026. Portable ultrasound diagnostics are expected to grow as healthcare systems move to point-of-care solutions.
Floor hinge accelerator technology: Added to the portfolio with a first win secured. Revenue expected in 2028. Floor hinge designs are expected to expand in EV applications, especially in international markets.
DrivePad technology: Secured an advanced development contract with a large Japanese OEM, adapting to future software-defined vehicle architectures.
Diversified end markets: Revenue from diversified end markets grew 16% year-over-year in Q4 2025, representing 59% of overall company revenue. Medical bookings were up 37%, and industrial bookings increased by 22%.
Transportation market: Sales declined by 7% in 2025 due to market dynamics in China and the commercial vehicle market. However, $100 million in new business awards were secured in Q4 2025, including accelerator module wins across multiple regions.
Aerospace and defense: Sales grew 20% year-over-year in 2025, with multiple orders for naval sonar, hydrophones, and RF filters. Bookings were down in Q4 but up 15% for the full year.
Gross margin improvement: Expanded gross margin by 150 basis points in Q4 2025 and for the full year, driven by operational improvements and favorable end market mix.
Cash flow generation: Generated $29 million in operating cash flow in Q4 2025 and $102 million for the full year. Returned $62 million to shareholders through dividends and share buybacks.
Diversification strategy: Continued focus on diversification, with diversified end markets now representing 59% of revenue in Q4 2025. Growth in medical, industrial, and defense markets supports this strategy.
Innovation in sensing technologies: Advancing next-generation sensing technologies for medical, industrial, and transportation applications, including minimally invasive medical treatments and EV applications.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Transportation Sales Decline: Transportation sales faced a 7% decline in 2025 compared to 2024, driven by market dynamics in China and the commercial vehicle market. This poses a challenge to revenue growth in this segment.
Defense Bookings Decline: Defense bookings were down in the fourth quarter of 2025, and sales for the quarter decreased by 4% compared to the same period in 2024. This decline is attributed to the timing of government funding cycles, which could impact future revenue.
Supply Chain Pressures: The company continues to monitor potential impacts from supply chain issues related to rare earth metals and semiconductors. While no immediate significant impact is reported, these pressures could pose risks to operations and product delivery.
Tariff and Geopolitical Environment: The company is closely monitoring the tariff and geopolitical environment, which could affect cost structures and pricing strategies, posing risks to profitability and market competitiveness.
Commercial Vehicle Demand Softness: General softness in commercial vehicle demand is expected in the first half of 2026, which could negatively impact transportation sales and overall revenue.
SyQwest Revenue Shortfall: SyQwest revenues in 2025 were lower than expected due to the timing of government contract awards, which could affect the company's ability to meet revenue targets in the defense segment.
EV Investment Recalibration: Certain OEMs are recalibrating their EV investments and launch dates, leading to slower interest in the company's eBrake product. This could delay growth in the electronic brake market.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Expectations: For full year 2026, sales are expected to be in the range of $550 million to $580 million.
Earnings Projections: Adjusted diluted EPS for 2026 is projected to be in the range of $2.30 to $2.45.
Medical Market Outlook: Continued momentum in therapeutics is expected, supported by expanded capacity. Increased volumes in portable ultrasound diagnostics and therapeutic products are anticipated in 2026.
Aerospace and Defense Market Outlook: Revenue growth is expected in 2026 due to backlog, SyQwest capabilities, and normalization of government funding. Decision-making and funding are anticipated to improve.
Industrial Market Outlook: Demand is expected to remain healthy in 2026, benefiting from long-term megatrends of automation and connectivity.
Transportation Market Outlook: Production volumes are expected to be flat to marginally down in 2026. General softness in commercial vehicle demand is anticipated in the first half of 2026, with potential improvement in the second half. Revenue from floor hinge technology is expected in 2028.
Supply Chain and Geopolitical Monitoring: Potential impacts from supply chain issues related to rare earth metals and semiconductors are being monitored, though no significant immediate impact is expected.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Dividends: In total, we returned $62 million to shareholders through dividends and share buybacks in 2025.
Share Buybacks: During the quarter, we repurchased 398,000 shares of CTS stock totaling approximately $17 million. For the full year, we repurchased approximately 1.4 million shares totaling $57 million. We have another $90 million remaining under our current share repurchase program.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are the assumptions within the 2026 guidance regarding the smart actuator and customer preferences for dual sourcing?
A:The company is continuing on both the legacy platform and the new platform launched last year. The new platform is being launched across different engine platforms, and cost reduction efforts are being enhanced in the second half of the year.
Q:Are there any insights into new products in transportation or other diversified end markets for 2026?
A:In transportation, the company secured approximately $100 million in new business awards, including accelerator modules, brake applied sensing, and floor hinge products, with revenue from some products expected in 2028. They are advancing on current sensing and DrivePad development. In medical, there is strong momentum in therapeutics and diagnostics, with collaborations on product development and launches in connectivity components for aerospace and defense.
Q:Was there any revenue deferral from Q4 into Q1 for SyQwest?
A:No, the reference was to the timing of government funding in 2025, which was lighter than expected. Revenue is expected to normalize in 2026, with good contracts in the pipeline.
Q:What is the net new product introduction relative to the offset of programs ending their lifecycle in 2026?
A:No specific number was provided. Revenue recognition is quicker on the diversified side, while transportation products take 2-3 years. New products and customers are contributing to growth, with diagnostics and portable ultrasound seen as growth markets.
Q:Is there improved visibility in industrial opportunities compared to three months ago?
A:Yes, visibility is improving steadily, with a book-to-bill ratio of 1.11 and bookings up 22%.
Q:What is the outlook for the transportation sector in 2026?
A:The company is cautious and has not called a bottom yet. Commercial vehicle improvement was seen in Q4, with the first half of 2026 expected to be lighter than the second half. The light vehicle market is expected to be flat to slightly down.
Q:What is the company seeing in the M&A market?
A:The company is actively working on the pipeline, focusing on diversification and niche technologies for transportation. Valuations remain high, and they are looking for the right assets.
Q:What is the assessment of markets by geography excluding transportation?
A:Good momentum is expected across diversified markets globally. Defense is focused in North America and Europe, while medical and industrial markets show strong momentum worldwide.
Q:How does the company characterize matching end demand and sales toward inventory rebuild in industrial and distributor markets?
A:Solid demand and year-over-year increases are observed. Customers are actively managing inventory, with some optimizing their levels.
Q:What is the latest market assessment of the China transportation market?
A:The market has reached a new normal. The company works with Japanese transplant OEMs and some local Chinese customers. A local team in China is engaged in new product development to address the market's fast pace.
Q:Review of Unclear Management Responses
A:Management avoided providing a specific number for the net new product introduction relative to the offset of programs ending their lifecycle in 2026. Additionally, the response regarding the M&A market was vague, with no concrete updates or details provided.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
China
OEM
OEMs
application
backlog level
booking backlog
cash
component
cost
demand
distribution
energy efficiency
floor hinge
funding
generation
health care
industry
market award
market momentum
nature
opportunity
portfolio product
portfolio win
precision
product win
progress
prospect
sensing capability
sensing technology
sensor
solution
strength
supplier
technology portfolio
term
vehicle
volume
CTS Transcript
CTS Corporation (CTS) Q4 2025 Earnings Call Transcript
Positive2-10
The earnings call summary indicates strong financial performance with increased sales in key markets like Medical and Industrial. Despite a decline in Transportation, new business awards and operational efficiencies improved EBITDA margins. The Q&A session highlighted strong demand and product development, though some management responses lacked clarity. Overall, the positive sales growth, improved margins, and strategic advancements in diversified markets suggest a positive stock price movement in the short term.
CTS Corporation (CTS) Q3 2025 Earnings Call Transcript
Unknown10-28
The earnings call reflects mixed signals: while aerospace, defense, industrial, and medical markets show strong performance, the transportation sector struggles, and EPS guidance was lowered due to tax impacts. Positive aspects include strong market growth and the SyQwest acquisition meeting expectations, but the adverse tax impact and transportation market softness temper enthusiasm. The Q&A session highlighted some concerns, such as unclear management responses and ongoing tax issues. Given the balance of positive and negative factors, the stock price is likely to remain stable over the next two weeks.
CTS Corporation (CTS) Q2 2025 Earnings Call Transcript
Positive7-24
The earnings call showed positive financial performance with improved EBITDA and gross margin, strong aerospace and medical sales, and shareholder returns. Despite transportation sales decline, guidance remains optimistic. Analysts' Q&A highlighted growth in therapeutics and potential recovery in transportation. The integration of SyQwest and operational efficiency are progressing well. Overall, the positive financial metrics and optimistic guidance suggest a likely stock price increase in the near term.
CTS Corporation (CTS) Q1 2025 Earnings Call Transcript
Unknown4-30
The earnings call presents a mixed sentiment. Positive elements include a strong book-to-bill ratio, revenue growth in diversified markets, and shareholder returns via buybacks. However, challenges such as declining transportation sales, geopolitical uncertainties, and a drop in EPS temper optimism. The Q&A session reveals some uncertainties, particularly around tariffs and the China market, but also highlights potential growth in diversified markets. Overall, the sentiment is balanced, leading to a neutral stock price prediction over the next two weeks.
CTS Slides
CTS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
